ODiSi™, a new type of treatment for ODS, has received FDA Breakthrough Device Designation, which is awarded to devices with the potential for "significant advantages over existing approved or cleared alternatives to include reducing or eliminating the need for hospitalization, improving patient quality of life, facilitating the patients’ ability to manage their own care or establishing long-term clinical efficiencies”.